Antidepressant Use During Pregnancy Associated With Some Adverse Outcomes in Newborns
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Antidepressant Use During Pregnancy Associated With Some Adverse Outcomes in Newborns

CHICAGO -- October 5, 2009 -- Exposure to a certain class of antidepressant medications during pregnancy may be associated with an increased risk of preterm birth, a low 5-minute Apgar score, and admission to the neonatal intensive care unit, according to a study published in the October issue of Archives of Pediatrics & Adolescent Medicine.

“Depression, antidepressants and lifestyle factors associated with depression may influence pregnancy outcomes and newborn health,” the authors wrote. “The safety profile of antidepressant medication in pregnancy is undetermined, but depression during pregnancy can be serious and has been associated with an increased maternal mortality.”

Selective serotonin reuptake inhibitors (SSRIs) have been used during pregnancy since the early 1990s and are recommended as the first choice for pregnant women in many countries.

Najaaraq Lund, MD, Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau, and Aarhus University, Aarhus, Denmark, and colleagues studied women receiving prenatal care from 1989 to 2006.

They compared birth outcomes including gestational age, birth weight, and Apgar score among babies born to 329 women who were treated with SSRIs, 4,902 who had a history of psychiatric illness but were not treated with SSRIs and 51,770 who had no history of psychiatric illness.

Women who took SSRIs during pregnancy gave birth an average of 5 days earlier and had twice the risk of preterm delivery as women with no history of psychiatric illness. Infants exposed to the medications in utero were significantly more likely than the 2 groups not exposed to have a 5-minute Apgar score of 7 or below or to be admitted to the neonatal intensive care unit (NICU). Head circumference and birth weight did not differ between the 3 groups.

SSRIs have been shown to readily cross the placenta and appear in the umbilical cord blood of infants whose mothers took them, the authors noted. Several previous observations have described withdrawal symptoms in infants born after exposure to the medications. In this study, exposed infants admitted to the NICU experienced symptoms that could be due to withdrawal from or adverse effects of SSRIs, including jitteriness, seizures, respiratory problems, infections and jaundice.

“The study justifies increased awareness to the possible effects of intrauterine exposure to antidepressants,” the authors concluded. “However, treatment of depression during pregnancy may be warranted and future studies need to distinguish between individual SSRIs to find the safest medication.”

SOURCE: Archives of Pediatric Adolescent Medicine

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities